Try a new search

Format these results:

Searched for:

in-biosketch:true

person:bangas01

Total Results:

827


Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease

Bangalore, Sripal; Fayyad, Rana; Laskey, Rachel; Demicco, David A; Deedwania, Prakash; Kostis, John B; Messerli, Franz H
BACKGROUND: Increasingly, apparent treatment-resistant hypertension has been recognized. However, much of the prevalence, predictors, and outcomes are largely unknown, especially in patients with coronary artery disease. METHODS: We evaluated 10,001 patients with coronary artery disease who were enrolled in the Treating to New Targets trial. Apparent treatment-resistant hypertension was defined as blood pressure >/=140 mm Hg despite 3 antihypertensive agents or <140 mm Hg with >/=4 antihypertensive agents. The primary outcome was major cardiovascular events (composite of fatal coronary heart disease, nonfatal myocardial infarction, resuscitated cardiac arrest, and stroke). RESULTS: Among the 10,001 patients in the trial, 1112 (11.1%) had apparent treatment-resistant hypertension. In a multivariable model adjusting for baseline differences, the treatment-resistant hypertension group had a 64% increase in primary outcome (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.39-1.94; P < .001), driven by a 69% increase in coronary heart disease death (HR, 1.69; 95% CI, 1.22, 2.34; P = .001) and 73% increase in nonfatal myocardial infarction (HR, 1.73; 95% CI, 1.39-2.16, P < .0001) when compared with the no apparent treatment-resistant hypertension group. In addition, patients with apparent treatment-resistant hypertension had a 71% increase in major coronary event (P < .0001), 45% increase in death (P = .001), 33% increase in heart failure (P = .05), 53% increase in any cardiovascular event (P < .0001), 60% increase in any coronary event (P < .0001), 68% increase in angina (P < .0001), and 51% increase in coronary revascularization (P < .0001) when compared with the no apparent treatment-resistant hypertension group. Results were largely similar whether the definition of apparent treatment-resistant hypertension was based on a blood pressure >/=140 mm Hg despite 3 agents or a blood pressure <140 mm Hg with >/=4 agents. CONCLUSIONS: In patients with coronary artery disease, apparent treatment-resistant hypertension is associated with a marked increase in the risk of cardiovascular morbidity and mortality, including an increase in all-cause death.
PMID: 24210549
ISSN: 0002-9343
CID: 745592

Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: A SCAI-based survey study of US interventional cardiologists

Chiang, Austin; Gada, Hemal; Kodali, Susheel K; Lee, Michael S; Jeremias, Allen; Pinto, Duane S; Bangalore, Sripal; Yeh, Robert W; Henry, Timothy D; Lopez-Cruz, Georgina; Mehran, Roxana; Kirtane, Ajay J
BACKGROUND: Great strides have been made in improving outcomes for patients with ST-elevation myocardial infarction (STEMI), predominately through initiatives focusing upon improving clinical processes "upstream" of percutaneous coronary intervention (PCI). The actual step-by-step mechanics of diagnostic angiography during STEMI and other aspects of the PCI procedure itself have received relatively little attention. OBJECTIVES AND METHODS: We hypothesized that there would be significant variation in how primary PCI for STEMI is performed in the United States. In order to better understand current US practice, an electronic survey consisting of seven focused questions was forwarded to 2,910 US interventional cardiologists who were members of the Society for Cardiovascular Angiography and Interventions (SCAI). RESULTS: Three hundred sixty-two responses were received (12.4%). Among respondents, the femoral artery was the preferred access site in 83% (vs. 17% radial). The use of a diagnostic catheter to visualize the non-culprit artery prior to using a guiding catheter for the culprit artery was the preferred approach for 58% of respondents, and an additional 23% preferred complete angiography with diagnostic catheters prior to guide insertion. However, a significant minority (19%) preferred starting directly with a guide catheter for the culprit artery and performing PCI prior to contralateral non-culprit artery visualization. Only 9% reported performing routine left ventriculography prior to PCI, with the majority (66%) choosing to perform ventriculography during/after PCI, and 25% reporting rare or no use of left ventriculography. Fewer than half of respondents (49%) reported routine aspiration thrombectomy use, despite a Class IIa ACC/AHA guidelines recommendation. CONCLUSIONS: There is significant variability in the self-reported mechanics of primary PCI by US interventional cardiologists. Some of this variability (e.g., sequence of catheters, and performance of left ventriculography prior to reperfusion) is not addressed by current guidelines/consensus documents, and may have clinical implications, reflecting the balance between the desire for timely reperfusion versus a more complete assessment of patient risk. (c) 2013 Wiley Periodicals, Inc.
PMID: 24273213
ISSN: 1522-1946
CID: 747112

Dietary salt reduction; further lowering of target lowers blood pressure but may increase risk

Messerli, Franz H; Bangalore, Sripal
PMID: 24001453
ISSN: 1356-5524
CID: 538962

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial

Bangalore, Sripal; Fayyad, Rana; Laskey, Rachel; Demicco, David; Deedwania, Prakash; Kostis, John B; Messerli, Franz H
AIM: Patients with resistant hypertension are at high risk for adverse cardiovascular events. Efforts have been focused on lowering the surrogate endpoint of blood pressure (BP) with scant focus on reduction of hard cardiovascular endpoints. However, whether or not intensive lipid lowering is beneficial for reducing the risk of cardiovascular events in this high-risk cohort is not known. METHODS AND RESULTS: We evaluated 10 001 patients with coronary artery disease and a low-density lipoprotein cholesterol level <130 mg/dL, randomized to atorvastatin 80 vs. 10 mg, enrolled in the Treating to New Targets trial. Treatment-resistant hypertension (TRH) was defined as BP >/=140 mmHg despite being on three antihypertensive agents or <140 mmHg on four or more agents. Subjects were followed up for a median duration of 4.9 years. The primary outcome was major cardiovascular events (composite of non-fatal myocardial infarction (MI), fatal coronary heart disease (CHD), resuscitated cardiac arrest, and stroke). Among the 10 001 patients in the trial, 1112 (11.1%) patients had TRH. Atorvastatin 80 mg, in patients with TRH, was associated with a significant reduction in the risk of the primary outcome (HR = 0.70; 95% CI 0.52-0.93; P = 0.01), driven largely by a significant reduction in CHD deaths (HR = 0.55; 95% CI 0.32-0.97; P = 0.04). In addition, atorvastatin 80 mg was associated with a reduction in major coronary events (HR = 0.67; 95% CI 0.49-0.93; P = 0.02), and any cardiovascular or coronary event and with a trend (P = 0.05) towards reduction in all-cause mortality (HR = 0.68; 95% CI 0.46-1.01) when compared with atorvastatin 10 mg. The results were similar when analysed for the two separate components of the TRH cohort. CONCLUSION: In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
PMID: 23990605
ISSN: 0195-668x
CID: 538972

Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis

Makani, Harikrishna; Bangalore, Sripal; Supariwala, Azhar; Romero, Jorge; Argulian, Edgar; Messerli, Franz H
AIMS: Angiotensin receptor blockers (ARBs) are available in different dosages and it is common clinical practice to uptitrate if blood pressure goal is not achieved with the initial dose. Data on the incremental antihypertensive efficacy with uptitration are scarce. It is also unclear if antihypertensive efficacy of losartan is comparable with other ARBs. METHODS AND RESULTS: We systematically reviewed PubMed/EMBASE/Cochrane databases for all randomized clinical trials until December 2012 reporting 24 h ambulatory blood pressure (ABP) for most commonly available ARBs in patients with hypertension. Reduction in ABP with ARBs was evaluated at 25% of the maximum (max) dose, 50% of the max dose, and at the max dose. Comparison was made between 24 h BP-lowering effect of losartan 50 and 100 mg and other ARBs at 50% max dose and the max dose, respectively. Sixty-two studies enrolling 15 289 patients (mean age 56 years; 60% men) with a mean duration of 10 weeks were included in the analysis. Overall, the dose-response curve with ARBs was shallow with decrease of 10.3/6.7 (systolic/diastolic), 11.7/7.6, and 13.0/8.3 mmHg with 25% max dose, 50% max dose, and with the max dose of ARBs, respectively. Losartan in the dose of 50 mg lowered ABP less well than other ARBs at 50% max dose by 2.5 mmHg systolic (P < 0.0001) and 1.8 mmHg diastolic (P = 0.0003). Losartan 100 mg lowered ABP less well than other ARBs at max dose by 3.9 mm Hg systolic (P = 0.0002) and 2.2 mmHg diastolic (P = 0.002). CONCLUSION: In this comprehensive analysis of the antihypertensive efficacy of ARBs by 24 h ABP, we observed a shallow dose-response curve, and uptitration marginally enhanced the antihypertensive efficacy. Blood pressure reduction with losartan at starting dose and at max dose was consistently inferior to the other ARBs.
PMCID:5994844
PMID: 23966312
ISSN: 0195-668x
CID: 538982

Optimal Treatment Strategies in Patients With Chronic Kidney Disease and Coronary Artery Disease: Insights From a Systemic Review and Meta-Analysis [Meeting Abstract]

Volodarskiy, Alexander; Kumar, Sunil; Bangalore, Sripal
ISI:000332162905372
ISSN: 1524-4539
CID: 1015532

Drug Eluting vs. Bare Metal Stents in Patients With Chronic Kidney Disease and Coronary Artery Disease: Insight From a Systematic Review and Meta-Analysis of Trials [Meeting Abstract]

Volodarskiy, Alexander; Kumar, Sunil; Bangalore, Sripal
ISI:000332162905369
ISSN: 1524-4539
CID: 1015522

Is dual Renin-Angiotensin-system blockade associated with increased risk of stroke? [Letter]

Makani, Harikrishna; Bangalore, Sripal; Sever, Peter; Messerli, Franz H
PMID: 24621979
ISSN: 2213-1779
CID: 836392

Percutaneous Coronary Intervention is Associated with Lower Mortality Compared with Optimal Medical Therapy in Patients with Stable Ischemic Heart Disease and Objective Evidence of Ischemia or Abnormal Fractional Flow Reserve: A Meta-Analysis of Randomized Controlled Trials [Meeting Abstract]

Kirtane, Ajay J.; Gada, Hemal; Bangalore, Sripal; Kereiakes, Dean; Stone, Gregg
ISI:000329845601130
ISSN: 0735-1097
CID: 816802

Lipid-Lowering in African Americans in ALLHAT-Optimism Bias? [Letter]

Messerli, Franz H; Bangalore, Sripal; Agarwal, Vikram
PMID: 24299694
ISSN: 1524-6175
CID: 700492